A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

November 6, 2026 updated by: Pliant Therapeutics, Inc.

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on an Immune Checkpoint Inhibitor (FORTIFY)

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.

The study will consist of 2 main parts:

  • Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
  • Part 2: Dose-expansion cohorts using Simon's 2-stage design

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

124

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Barcelona
      • Barcelona, Barcelona, Spain, 08023
        • Recruiting
        • Hospital Universitari Quirónsalud (NEXT Barcelona)
        • Contact:
      • Barcelona, Barcelona, Spain, 08023
        • Recruiting
        • START Barcelona - Hospital HM Nou Delfos
        • Contact:
      • Barcelona, Barcelona, Spain, 08035
        • Recruiting
        • Hospital Universitari Vall d'Hebron - VHIO
        • Contact:
    • La Rioja
      • Logroño, La Rioja, Spain, 26006
        • Recruiting
        • START Center for Cancer Research - La Rioja
        • Contact:
    • Madrid
      • Madrid, Madrid, Spain, 28040
        • Recruiting
        • START Madrid - Hospital Universitario Fundación Jiménez Díaz
        • Contact:
      • Madrid, Madrid, Spain, 28050
        • Recruiting
        • START Madrid - Centro Integral Oncológico Clara Campal
        • Contact:
    • Pozuelo de Alarcón
      • Madrid, Pozuelo de Alarcón, Spain, 28223
        • Recruiting
        • University Hospital Quironsalud Madrid (NEXT Madrid)
        • Contact:
    • Connecticut
      • New Haven, Connecticut, United States, 06511
        • Completed
        • Yale University
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20007
        • Recruiting
        • Georgetown University Medical Center
        • Contact:
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Recruiting
        • Winship Cancer Institute of Emory University
        • Contact:
    • Michigan
      • Grand Rapids, Michigan, United States, 49546
        • Recruiting
        • South Texas Accelerated Research Therapeutics (START)
        • Contact:
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University Medicine
        • Contact:
    • New Jersey
      • East Brunswick, New Jersey, United States, 08816
      • New Brunswick, New Jersey, United States, 08901
        • Recruiting
        • Rutgers Cancer Institute of New Jersey
        • Contact:
    • New York
      • Lake Success, New York, United States, 11042
        • Recruiting
        • START New York Long Island LLC
        • Contact:
    • North Carolina
      • Wilson, North Carolina, United States, 27893
        • Recruiting
        • Carolina Cancer Research Center
        • Contact:
    • South Dakota
      • Sioux Falls, South Dakota, United States, 57105
    • Tennessee
      • Nashville, Tennessee, United States, 37203
    • Texas
      • Austin, Texas, United States, 78758
      • Fort Worth, Texas, United States, 76104
        • Recruiting
        • START Center for Clinical Research
        • Contact:
      • Houston, Texas, United States, 77030
        • Recruiting
        • University of Texas MD Anderson Cancer Center
        • Contact:
      • Houston, Texas, United States, 77054
      • San Antonio, Texas, United States, 78229
        • Recruiting
        • UT Health San Antonio's Mays Cancer Center
        • Contact:
    • Utah
      • West Valley City, Utah, United States, 84119
    • Virginia
      • Fairfax, Virginia, United States, 22031
        • Recruiting
        • Inova Schar Cancer Institute
        • Contact:
      • Fairfax, Virginia, United States, 22031
    • Washington
      • Edmonds, Washington, United States, 98026
        • Recruiting
        • Swedish Cancer Institute Medical Oncology
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Has histologically or cytologically confirmed advanced or metastatic solid tumor
  2. Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
  3. Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
  4. Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
  5. At least 1 measurable lesion, as defined by RECIST v1.1
  6. Estimated survival of ≥3 months
  7. Have adequate bone marrow and organ function.
  8. A female participant is eligible to participate if she is not pregnant, not breastfeeding

Exclusion Criteria:

  1. Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
  2. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
  3. Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
  4. Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
  5. Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
  6. Has an active autoimmune disease that has required systemic treatment in the past 2 years
  7. Has known active CNS metastases (brain and/or leptomeningeal metastases)
  8. Has significant cardiac disease
  9. Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
  10. Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part 1 Dose Escalation - 250 mg BID

Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Experimental: Part 1 Dose Escalation - 500 mg BID

PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Experimental: Part 1 Dose Escalation - 1000 mg BID

PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Experimental: Part 1 Dose Escalation - 1000 mg TID

PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Experimental: Part 1 Dose Escalation - 2000 mg BID

PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Experimental: Part 2 Dose Expansion - NSCLC

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC)

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Experimental: Part 2 Dose Expansion - ccRCC

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC)

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Experimental: Part 2 Dose Expansion - TMB-high solid tumors

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors

PLN-101095 250 mg BID

PLN-101095 500 mg BID

PLN-101095 1000 mg BID

PLN-101095 1000 mg TID

PLN-101095 2000 mg BID

PLN-101095

Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Time Frame: First dose to 35 days

Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications.

First dose to 35 days
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Time Frame: Day 1 until 16 weeks after end of study treatment regimen

Proportion of participants with treatment-emergent adverse events and serious adverse events.

Day 1 until 16 weeks after end of study treatment regimen
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Time Frame: First dose to disease progression or death from any cause, whichever occurs first.

Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1.

First dose to disease progression or death from any cause, whichever occurs first.
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Time Frame: First dose to disease progression or death from any cause, whichever occurs first.

Proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1.

First dose to disease progression or death from any cause, whichever occurs first.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PK of PLN-101095 monotherapy in Parts 1 and 2
Time Frame: Day 14, 0 to up to 12 hours

Maximum drug concentration (Cmax)

Day 14, 0 to up to 12 hours
PK of PLN-101095 monotherapy in Parts 1 and 2
Time Frame: Day 14, 0 to up to 12 hours

Time to Cmax (Tmax)

Day 14, 0 to up to 12 hours
PK of PLN-101095 monotherapy in Parts 1 and 2
Time Frame: Day 14, 0 to up to 12 hours

Area under the concentration-time curve (AUC0-τ)

Day 14, 0 to up to 12 hours
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Time Frame: First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first

Duration of response (DOR) for objective responders

First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Time Frame: First dose to progression or death from any cause, whichever occurs first

Time on treatment (TOT) for objective responders

First dose to progression or death from any cause, whichever occurs first

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Pliant Therapeutics Medical Monitor, Pliant Therapeutics, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 30, 2023

Primary Completion (Estimated)

June 1, 2030

Study Completion (Estimated)

June 1, 2030

Study Registration Dates

First Submitted

January 26, 2024

First Submitted That Met QC Criteria

February 13, 2024

First Posted (Actual)

February 21, 2024

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • PLN-101095-ONC-101

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.